The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Leptomeningeal carcinomatosis
Open accessAbstract
Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This disorder is being diagnosed with increasing frequency as patients live longer and as neuro-imaging studies improve. The most common cancers to involve the leptomeninges are breast cancer, lung cancer, and melanomas. Tumour cells reach the leptominges by hematogenous spread or by direct extension from pre-existing lesions and are then disseminated throughout the neuroaxis by the flow of the cerebrospinal fluid. Patients present with signs and symptoms from injury to nerves that traverse the subarachnoid space, direct tumour invasion into the brain or spinal cord, alterations in blood supply to the nervous system, obstruction of normal cerebrospinal fluid (CSF) flow pathways, or general interference with brain function. The diagnosis is most commonly made by lumbar puncture although the CSF cytology is persistently negative in about 10% of patients with leptomeningeal carcinomatosis. Radiologic studies may reveal subarachnoid masses, diffuse contrast enhancement of the meninges, or hydrocephalus without a mass lesion. Without treatment, the median survival of patients with this disorder is 4-6 weeks and death occurs from progressive neurologic dysfunction. Early diagnosis and therapy is critical to preserving neurologic function. Radiation therapy to symptomatic sites and disease visible on neuroimaging studies and intrathecal chemotherapy increases the median survival to 3-6 months. The major favorable prognostic factors include excellent performance status, absence of serious fixed neurologic deficits, normal CSF flow scans, and absent or responsive systemic tumour. Aggressive therapy for this disorder is often accompanied by a necrotizing leukoencephalopathy which becomes symptomatic months after treatment with radiation and intrathecal methotrexate. As currently available therapies are toxic and provide limited benefits, novel approaches are being studied. Further information on the mechanisms of neurotoxicity from antineoplastic agents is critical to providing better outcomes for this increasing common complication of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients
Wasserstrom, W. R., Glass, J. P., & Posner, J. B. (1982) · Cancer · doi:10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7 · Cited by 1,124
Shapiro, W. R., Young, D. F., & Mehta, B. M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197507242930402 · Cited by 681
Hitchins, R. N., Bell, D. R., Woods, R. L., & Levi, J. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1655 · Cited by 352
Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia
Bleyer, W. A., Drake, J. C., & Chabner, B. A. (1973) · New England Journal of Medicine · doi:10.1056/nejm197310112891503 · Cited by 337
Glantz, M. J., Cole, B. F., Recht, L., Akerley, W., Mills, P., Saris, S., Hochberg, F., Calabresi, P., & Egorin, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1561 · Cited by 322
Kaplan, J. G., DeSouza, T. G., Farkash, A., Shafran, B., Pack, D., Rehman, F., Fuks, J., & Portenoy, R. (1990) · Journal of Neuro-Oncology · doi:10.1007/bf02341153 · Cited by 308
The central nervous system in childhood leukemia: I. The arachnoid
Price, R. A., & Johnson, W. W. (1973) · Cancer · doi:10.1002/1097-0142(197303)31:3<520::aid-cncr2820310306>3.0.co;2-2 · Cited by 280
Glantz, M., Hall, W. A., Cole, B. F., Chozick, B. S., Shannon, C., Wahlberg, L. U., Akerley, W., Marin, L., & Choy, H. (1995) · Cancer · Cited by 192
Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis
Grossman, S. A., Trump, D. L., Chen, D. C. P., et al. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90404-1 · Cited by 161
Self-citationExtended CSF cytarabine exposure following intrathecal administration of DTC 101.
Kim, S., Chatelut, É., Kim, J. C., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2186 · Cited by 153
Cited by
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Aparicio, A., & Chamberlain, M. C. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0081-7 · Cited by 487
Leptomeningeal metastases in non-small-cell lung cancer
Cheng, H., & Perez-Soler, R. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30689-7 · Cited by 304
Boogerd, W., van den Bent, M. J., Koehler, P. J., Heimans, J. J., van der Sande, J. J., Aaronson, N. K., Hart, A. A. M., Benraadt, J., & Vecht, C. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.012 · Cited by 286
Imaging of Spinal Metastatic Disease
Shah, L. M., & Salzman, K. L. (2011) · International Journal of Surgical Oncology · doi:10.1155/2011/769753 · Cited by 262
Leptomeningeal metastasis from systemic cancer: Review and update on management
Wang, N., Bertalan, M. S., & Brastianos, P. K. (2018) · Cancer · doi:10.1002/cncr.30911 · Cited by 262
Kumthekar, P., Tang, S.-C., Brenner, A. J., Kesari, S., Piccioni, D. E., Anders, C., Carrillo, J., Chalasani, P., Kabos, P., Puhalla, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3258 · Cited by 250
Waki, F., Ando, M., Takashima, A., Yonemori, K., Nokihara, H., Miyake, M., Tateishi, U., Tsuta, K., Shimada, Y., Fujiwara, Y., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9758-3 · Cited by 145
Lee, Y., Han, J.-Y., Kim, H. T., Yun, T., Lee, G. K., Kim, H. Y., & Lee, J. S. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1199-y · Cited by 36
Metadata
- Authors
- Grossman, S. A., & Krabak, M. J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 25
- Issue
- 2
- Pages
- 103-119
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W3022072485
- Cited by
- 529
- References
- 20
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.